Cholesterol-Drug Developer Aegerion Pharmaceuticals, Inc. Revives Plan for $86.3M IPO

Wall Street Journal -- Aegerion Pharmaceuticals Inc. re-registered to hold an $86.3 million initial public offering of shares, after abandoning a similar plan as the stock-market plunged in late 2008.

MORE ON THIS TOPIC